Drug Name Generic Name J-Code Unclassified Drugs in excess of $10,000

Size: px
Start display at page:

Download "Drug Name Generic Name J-Code Unclassified Drugs in excess of $10,000"

Transcription

1 Unclassified Drugs in excess of $10,000 J3490 Unclassified Biologics in excess of $10,000 J3590 Revenue Codes in excess of $10,000 R250 - R259 ABRAXANE paclitaxel protein-bound J9264 & J9267 ACTEMRA tocilizumab J3262 ACTHAR repository corticotropin J0800 ACTIMMUNE interferon gamma-1b J9216 ADAGEN pegademase bovine J2504 ADCETRIS brentuximab vedotin J9042 ADCIRCA tadalafil oral ADEMPAS riociguat oral ADVATE (All Forms) antihemophilic factor, recombinant J7186 AFINITOR everolimus oral J7527 AFINITOR DISPERZ everolimus oral soluble J7527 ALECENSA alectinib oral ALPHANINE SD factor IX (human) J7193, J7194, J7200, J7201, AMPYRA dalfampridine (4-aminopyridine) oral APOKYN apomorphine hydrochloride J0364 ARCALYST rilonacept J2793 ATRIPLA efavirenz/emtricitabine/tenofovir disoproxil fumarate oral AUBAGIO teriflunomide oral AVASTIN bevacizumab J9035 AVONEX interferon beta-1a J1826 & Q3027 AVONEX PEN KIT interferon beta-1a J1826 & Q3027 BENEFIX factor IX (recombinant) J7195 BENLYSTA belimumab J0490 BERINERT C1 inhibitor, human BETASERON interferon beta-1b J1830 BETHKIS tobramycin oral inhalation J7682 & J7685 BICNU carmustine (BCNU) J9050 BLINCYTO blinatumomab J9039 BOSULIF bosutinib oral BRAVELLE urofollitropin J3355 Page 1 of 7 7/5/2017

2 CAPRELSA vandetanib oral CARIMUNE NF intravenous CAYSTON aztreonam inhalation CEREZYME imiglucerase CETROTIDE cetrorelix acetate CIMZIA certolizumab pegol CIMZIA PREFL KIT certolizumab pegol J0717 & J0718 CINQAIR reslizumab CINRYZE C1 inhibitor, human COMETRIQ cabozantinib malate oral COMPLERA emtricitabine/rilpivirine hydrochloride/tenofovir disoproxil fumarate oral COPAXONE* glatiramer acetate J1595 Corlanor ivabradine oral COSENTYX secukinumab COSENTYX PEN INJ secukinumab COTELLIC cobimetinib fumarate oral DAKLINZA daclatasvir dihydrochloride oral ELAPRASE idursulfase J1743 ELOCTATE antihemophilic factor, recombinant (Fc Fusion Protein) J7186 ENBREL SRCLK* etanercept J1438 ENBREL* etanercept J1438 Enstilar calcipotriene/betamethasone dipropionate topical ENTYVIO* vedolizumab J3380 EPCLUSA sofosbuvir/velpatasvir oral EPOGEN epoetin alfa recombinant (erythropoietin; EPO) J0885 & J0886 ERIVEDGE vismodegib oral ESBRIET pirfenidone oral Evzio naloxone hydrochloride J2310 EXJADE deferasirox oral EXTAVIA interferon beta-1b J1830 EYLEA aflibercept ophthalmic J0178 FABRAZYME agalsidase beta J0180 Page 2 of 7 7/5/2017

3 FARYDAK panobinostat lactate oral Femara (brand only) Brand Only - generic is letrozole oral FIRAZYR icatibant acetate J1744 FORTEO teriparatide J3110 FUZEON enfuvirtide J1324 GAMMAGARD GAMMAGARD SD GAMUNEX GAMUNEX C GAZYVA obinutuzumab J9301 GENVOYA elvitegravir/cobicistat/emtricitabine/tenofo vir alafenamide fumarate oral GILENYA fingolimod hydrochloride oral GLATOPA glatiramer acetate J1595 & J7199 GLEEVEC imatinib mesylate oral S0088 HARVONI ledipasvir/sofosbuvir oral HELIXATE FS antihemophilic factor, recombinant J7186 HERCEPTIN trastuzumab J9355 HIZENTRA* subcutaneous HUMATE-P antihemophilic factor/von willebrand factor complex (factor VIII/VWF; AHF/VWF) J7186 HUMATROPE somatropin J2941 HUMIRA adalimumab J0135 HUMIRA PEN adalimumab J0135 HYCAMTIN topotecan hydrochloride /oral J8705 & J9351 HYQVIA /hyaluronidase subcutaneous & J3470 IBRANCE palbociclib oral ILARIS canakinumab J0638 ILUVIEN fluocinolone acetonide ophthalmic J7313 Page 3 of 7 7/5/2017

4 Imatinib (generic Gleevec) imatinib mesylate oral S0088 IMBRUVICA ibrutinib oral IMLYGIC talimogene laherparepvec J9325 INCIVEK telaprevir oral INLYTA axitinib oral INTELENCE etravirine oral ISENTRESS raltegravir potassium oral Jadenu deferasirox oral JAKAFI ruxolitinib phosphate oral KADCYLA ado-trastuzumab emtansine J9354 KALETRA lopinavir/ritonavir oral KALYDECO ivacaftor oral KYPROLIS carfilzomib J9047 LEMTRADA alemtuzumab J0202 & J9010 LETAIRIS ambrisentan oral LONSURF trifluridine/tipiracil hydrochloride oral LUCENTIS ranibizumab intravitreal J2778 LYNPARZA olaparib oral MAKENA hydroxyprogesterone caproate J1725 MATULANE procarbazine hydrochloride (N- Methylhydrazine; MIH) oral S0182 MEKINIST trametinib dimethyl sulfoxide oral NEORAL cyclosporine (cyclosporin A) oral J7502 & J7515 NEULASTA pegfilgrastim J2505 NEUPOGEN filgrastim (granulocyte colony-stimulating J1440, J1441, J1442, factor; G-CSF) J1446, J1447 NEXAVAR sorafenib tosylate oral NINLARO ixazomib oral NORDITROPIN (ALL FORMS)* somatropin J2941 NORTHERA droxidopa oral NPLATE romiplostim J2796 NUCALA mepolizumab J2182 NUTROPIN (ALL FORMS)* somatropin J2941 Nutropin Nuspin AQ* somatropin J2941 OCALIVA obeticholic acid oral OCREVUS ocrelizumab Page 4 of 7 7/5/2017

5 ODEFSEY emtricitabine/rilpivirine hydrochloride/tenofovir alafenamide fumarate oral ODOMZO sonidegib oral OFEV nintedanib ethanesulfonate oral OLYSIO simeprevir sodium oral OPDIVO nivolumab J9299 OPSUMIT macitentan oral ORENCIA abatacept J0129 ORENCIA-C abatacept J0129 ORENITRAM treprostinil diolamine oral J3285 & J7686 ORKAMBI lumacaftor/ivacaftor oral OTEZLA apremilast oral PEG-INTRON peginterferon alfa-2b S0148 PERJETA pertuzumab J9306 Pertzye digestive enzymes oral PLEGRIDY peginterferon beta-1a POMALYST pomalidomide oral PREZCOBIX darunavir/cobicistat oral PREZISTA darunavir ethanolate oral PRIVIGEN intravenous PROLIA denosumab J0897 PROMACTA eltrombopag olamine oral PULMOZYME dornase alfa (recombinant human deoxyribonuclease; rhdnase) inhalation J7639 RAVICTI glycerol phenylbutyrate oral Rayos prednisone oral J7506 & J7512 REBIF interferon beta-1a J1826 & Q3026 & Q3028 REBIF REBIDO interferon beta-1a J1826 & Q3026 & Q3028 REBIF TITRTN INJ PACK interferon beta-1a J1826 & Q3026 & Q3028 RELISTOR methylnaltrexone bromide oral J2212 REMICADE (Inflectra is biosimilar to Remicade) infliximab J1745 REMODULIN treprostinil sodium J3285 & J7686 REPATHA (all 3 versions) evolocumab REVATIO sildenafil citrate /oral REVLIMID lenalidomide oral REYATAZ atazanavir sulfate oral Page 5 of 7 7/5/2017

6 RIBAVIRIN ribavirin oral/inhalation RITUXAN rituximab J9310 SABRIL vigabatrin oral SANDIMMUNE cyclosporine (cyclosporin A) oral/ J7502 & J7515 SANDOSTATIN octreotide acetate J2353 & J2354 SENSIPAR cinacalcet hydrochloride oral SIMPONI golimumab J1602 SOMAVERT pegvisomant SOVALDI sofosbuvir oral SPINRAZA nusinersen SPRYCEL dasatinib oral STELARA ustekinumab J3357 STIVARGA regorafenib oral STRIBILD elvitegravir/cobicistat/emtricitabine/tenofo vir disoproxil fumarate oral SUCRAID sacrosidase oral SUPPRELIN LA* histrelin acetate subcutaneous SUTENT sunitinib malate oral Syprine trientine hydrochloride oral TAFINLAR dabrafenib mesylate oral TALTZ ixekizumab TARCEVA erlotinib hydrochloride oral TASIGNA nilotinib hydrochloride oral TECENTRIQ atezolizumab 9999, J3590, J3490, C948 TECFIDERA* dimethyl fumarate oral THALOMID thalidomide oral THYROGEN thyrotropin alfa J3240 TIVICAY dolutegravir sodium oral TOBI tobramycin oral inhalation J7682 TOBI PODHALR tobramycin oral inhalation J7682 Tobramycin inhaled (generic Tobi) tobramycin oral inhalation J7682 Topotecan (generic Hycamtin) topotecan hydrochloride /oral J8705 & J9351 TRIUMEQ abacavir sulfate/dolutegravir sodium/lamivudine oral TYKERB lapatinib ditosylate oral TYSABRI natalizumab J2323 Page 6 of 7 7/5/2017

7 TYVASO treprostinil inhalation J3285 & J7686 VECTIBIX panitumumab J9303 VELCADE bortezomib J9041 VENCLEXTA venetoclax oral Viberzi eluxadoline oral VIEKIRA ombitasvir/paritaprevir/ritonavir/dasabuvir sodium oral VIREAD tenofovir disoproxil fumarate oral Vivaglobin VIVITROL naltrexone J2315 VOTRIENT pazopanib hydrochloride oral VPRIV velaglucerase alfa J3385 VRAYLAR cariprazine oral XALKORI crizotinib oral XELJANZ tofacitinib citrate oral XENAZINE tetrabenazine oral XGEVA denosumab J0897 XIAFLEX collagenase clostridium histolyticum J0775 Xifaxan* rifaximin oral XOLAIR omalizumab J2357 XTANDI enzalutamide oral XYREM sodium oxybate oral ZELBORAF vemurafenib oral ZEMAIRA alpha 1-proteinase inhibitor, human (alpha 1-antitrypsin) J0256 ZEPATIER elbasvir/grazoprevir oral ZOLADEX goserelin acetate implant J9202 ZORTRESS everolimus oral J7527 ZYDELIG idelalisib oral ZYKADIA ceritinib oral ZYTIGA abiraterone acetate oral Page 7 of 7 7/5/2017

List of Designated High-Cost Drugs

List of Designated High-Cost Drugs List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at

More information

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC) INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193

More information

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015 J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,

More information

Specialty Drugs. The following is a list of medications that are considered to be specialty drugs. Specialty drugs

Specialty Drugs. The following is a list of medications that are considered to be specialty drugs. Specialty drugs Specialty Drugs The following is a list of medications that are considered to be specialty drugs. Specialty drugs include self-administered injectables, medications that are high cost, and/or medications

More information

Aetna Better Health. Specialty Drug Program

Aetna Better Health. Specialty Drug Program Aetna Better Health is managed through CVS Health Specialty Pharmacy. The Specialty pharmacies fill prescriptions and ship drugs for complex medical conditions, including multiple sclerosis, rheumatoid

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Self Administered Oncology Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior

More information

Specialty Drugs. The specialty drug list below is effective June 5, 2018 and is subject to change at any time.

Specialty Drugs. The specialty drug list below is effective June 5, 2018 and is subject to change at any time. Specialty Drugs The following is a list of medications that are considered specialty drugs. Specialty drugs include self-administered injectables, medications that are high cost, and/or medications that

More information

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea

More information

MedStar Medicare Choice Pharmacy Services

MedStar Medicare Choice Pharmacy Services Pharmacy Services 1 MedStar Medicare Choice Pharmacy Services Table of Contents At a Glance..page 2 Pharmacy Policies..page 4 Medicare Choice Pharmacy Programs..page 6 Where to Obtain Prescriptions..page

More information

2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017

2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017 Abstral Actemra Adcirca Adempas Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio Beleodaq

More information

2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018

2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018 Abstral Actemra Adcirca Adempas Aliqopa Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio

More information

BCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015

BCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015 Prior Authorization List 2015 Participating providers are responsible to furnish or arrange health care services with other participating healthcare facilities or providers. Prior authorization requests

More information

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW

More information

PA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*

PA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3* ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0364T 0365T 0366T 0367T 0373T 0374T H2020 96116

More information

acromegaly Drugs Covered Uses Exclusion Criteria Required Medical Information Age Restriction Prescriber Restriction Coverage Duration

acromegaly Drugs Covered Uses Exclusion Criteria Required Medical Information Age Restriction Prescriber Restriction Coverage Duration acromegaly SIGNIFOR, SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 120 MG/0.5 ML, 60 MG/0.2 ML, 90 MG/0.3 ML, SOMAVERT SUBCUTANEOUS RECON SOLN 15 MG, 20 MG, 25 MG, 30 MG All medically accepted indications not

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Self Administered Oncology Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior

More information

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607) Overview of Cancer Laura Bingell RN Transition Center Nurse for MFP (607)962-8225 lbingell@ilny.org What is Cancer? A collection of related diseases in which some of the body s cells begin to divide abnormally

More information

Percent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris. Amprya dalfampridine 10 mg 60 count bottle

Percent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris. Amprya dalfampridine 10 mg 60 count bottle Department of General Services Procurement Division Contract # 01-14- 65-57 Pharmaceutical Acquisitions Section Exhibit G-1 April 30, 2015 Walgreens Specialty Pharmacy LLC, Products Pricing Crescent Healthcare,

More information

Exclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or

Exclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or Noridian Healthcare Solutions, LLC Jurisdiction F Part B Self-Administered Drug (SAD) Exclusion List (A53033); Effective 8/7/2017 The following medications are considered self-administered and are not

More information

SELF-ADMINISTERED MEDICATIONS LIST

SELF-ADMINISTERED MEDICATIONS LIST SELF-ADMINISTERED MEDICATIONS LIST Table of Contents Page Last Updated: January 23, 2019 INSTRUCTIONS FOR USE... 1 APPLICABLE CODES... 1 Related Commercial Policy LIST HISTORY/REVISION INFORMATION... 5

More information

ACAMPROSATE (CAMPRAL)

ACAMPROSATE (CAMPRAL) ACAMPROSATE (CAMPRAL) ACAMPROSATE CALCIUM Creatinine clearance less than 30 PAGE 1 LAST UPDATED 06/2016 ADALIMUMAB (HUMIRA) HUMIRA, HUMIRA PEDIATRIC CROHN'S, HUMIRA PEN, HUMIRA PEN CROHN'S-UC-HS, HUMIRA

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Self Administered Oncology Agents Page 1 of 19 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior

More information

ORAL ONCOLOGY CRITERIA

ORAL ONCOLOGY CRITERIA ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

PA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3*

PA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3* ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0373T H2020 96116 96112 96113 96121 96130 96131

More information

DRUGS REQUIRING PRIOR AUTHORIZATION

DRUGS REQUIRING PRIOR AUTHORIZATION DRUGS REQUIRING PRIOR AUTHORIZATION Medication Abstral Actemra Acthar Gel Actiq* Adcirca Adderall Adderall XR Addyi Adempas Adipex* Adzenys XR-ODT Afinitor Afinitor Alecensa Alecensa Ampyra Androderm AndroGel

More information

OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT. Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC

OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT. Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC 1 Conflicts of Interest Damon Hostin Has no real or apparent conflicts

More information

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate

More information

Pharmacy Services Request Types

Pharmacy Services Request Types FOR DRUG REQUESTS, ONLY-- * NOTE: Only those drugs administered by a healthcare provider and billed medically would be entered via CareAffiliate. * Oral drugs would not be administered by a healthcare

More information

Specialty Pipeline Update

Specialty Pipeline Update CLINICAL SOLUTIONS Drug Insights > September 2015 Specialty Pipeline Update New Drug Information Xuriden (uridine triacetate): The Food and Drug Administration (FDA) approved Wellstat Therapeutics oral

More information

ORAL ONCOLOGY CRITERIA

ORAL ONCOLOGY CRITERIA ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

Pharmacy Medical Necessity Guidelines: Oral Cancer Medications

Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Pharmacy Medical Necessity Guidelines: Effective: February 18, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)

More information

Specialty Pipeline Update

Specialty Pipeline Update Specialty Pipeline Update D Drug Insights > March 2016 New drug information Odefsey (emtricitabine, tenofovir alafenamide, rilpivirine): The Food and Drug Administration (FDA) approved Gilead s combination

More information

METABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST

METABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST PRIOR AUTHORIZATION LIST (SUBJECT TO CHANGE) MEDICATION THERAPEUTIC CATEGORY MODULE ACTEMRA INFLAMMATORY CONDITIONS ACTEMRA ADCIRCA PULMONARY HYPERTENSION PDE-5 INHIBITORS FOR PAH ADDYI SEXUAL DISORDERS

More information

INJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions

INJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions J9190 5-FU fluorouracil None. J0401 ABILIFY MAINTENA aripiprazole i.v. J9264 ABRAXANE paclitaxel protein bound J3262 ACTEMRA IV tocilizumab Yes, through Navitus. Restricted to (in at least consultation

More information

March 2017 Pharmacy & Therapeutics Committee Decisions

March 2017 Pharmacy & Therapeutics Committee Decisions UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed

More information

Lista de medicamentos especializados

Lista de medicamentos especializados Lista de medicamentos especializados Vigencia: 1o. de enero de 2016 A continuación se listan, en orden alfabético, los medicamentos de especialidad recetados más frecuentemente. Los medicamentos de especialidad

More information

LIMITED DISTRIBUTION MEDICATIONS

LIMITED DISTRIBUTION MEDICATIONS ACTEMRA IV (USSC can dispense 162 mg PFS) ACTHAR HP ACTIMMUNE ADAGEN ADCETRIS CVS Specialty 1-800-237-2767 1-800-237-2767 ADEMPAS ADVATE ALDURAZYME ALECENSA ALIQOPA ALUNBRIG AMPYRA APOKYN ARALAST NP ARCALYST

More information

Specialty Pipeline Update

Specialty Pipeline Update CLINICAL SOLUTIONS Drug Insights > December 2015 Specialty Pipeline Update New Drug Information Alecensa (alectinib): The Food and Drug Administration (FDA) approved Genentech s orally administered ALK

More information

Specialty Pharmacy Pipeline

Specialty Pharmacy Pipeline Specialty Pharmacy Pipeline Drugs to Watch Anticipated Launches Q1 Q2 2017 Atopic Dermatitis Dupixent (dupilumab) Subcutaneous injection Regeneron Pharmaceuticals/Sanofi moderate-to-severe atopic dermatitis

More information

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate

More information

P&T/Formulary Committee Actions (1Q18)

P&T/Formulary Committee Actions (1Q18) P&T/Formulary Committee s (1Q18) 1Q2018 Marketplace Standard (HIEx) Additions and/or Revisions effective: April 1, 2018 Deletions effective: April 1, 2018 for NEW member prescriptions; July 1, 2018 for

More information

Pharmacy Policy Bulletin

Pharmacy Policy Bulletin Pharmacy Policy Bulletin Title: Policy #: Oncology Agents Rx.01.67 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some

More information

MEDICAL NECESSITY GUIDELINE

MEDICAL NECESSITY GUIDELINE PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205

More information

SPECIALTY PHARMACY Master Clinical Drug List

SPECIALTY PHARMACY Master Clinical Drug List Abraxane J9264 Provider ONCOLOGY None NO Actemra J3262 Provider ARTHRITIS PA - all YES Acthar HP Gel J0800 Prov/Self Med/Pharm ENDOCRINE/METABOLIC PA - all YES Adagen J2504 Provider ENZYME DISORDERS None

More information

Injections Requiring Prior Authorization

Injections Requiring Prior Authorization At VIVA Health, we strive to keep our provider network informed of any changes. Most of you may currently obtain prior authorizations for administered injections. Below is a list of injection, infusion,

More information

CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description

CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY Coverage Guideline Policy & Procedure HIM.PA.32 Long acting stimulants (Adderall XR, Dexedrine, Metadate CD, Ritalin

More information

ANTI-PARIKSON'S AGENT- DUOPA

ANTI-PARIKSON'S AGENT- DUOPA ANTI-PARIKSON'S AGENT- DUOPA DUOPA Patient has a diagnosis of Parkinson's disease. Patient is levodopa-responsive.patient experiences disabling Off periods for a minimum of 3 hours/day. Disabling Off"

More information

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary One mission: you Changes July 1, 2018 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for

More information

Buckeye Health Plan (MMP) 2016 Prior Authorization Criteria

Buckeye Health Plan (MMP) 2016 Prior Authorization Criteria Buckeye Health Plan (MMP) 2016 Prior Authorization Instructions: 1. With this file, at the top, click Edit, then click Find. 2. In the Find box type the name of the medication you want to find. 3. Click

More information

ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year

ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

Descriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin

Descriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin Self-Administered Drug Exclusion List R2 This article from Medicare A News, Issue 2106 dated January 23, 2013 and Medicare B News, Issue 283 dated January 23, 2013 is being revised to add Acthar ACTH gel

More information

January 2018 Pharmacy & Therapeutics Committee Decisions

January 2018 Pharmacy & Therapeutics Committee Decisions UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed

More information

Pulmonary Hypertension Weight Loss Skin Conditions. Skin Conditions Multiple Sclerosis Endocrine Disorder. Endocrine Disorder.

Pulmonary Hypertension Weight Loss Skin Conditions. Skin Conditions Multiple Sclerosis Endocrine Disorder. Endocrine Disorder. Prior Authorization PricewaterhouseCoopers The following medications may require prior authorization prior to dispensing at a participating retail pharmacy or through the Express Scripts Pharmacy home

More information

Specialty Overview by Prior Authorization Approval or Denial 2nd Quarter 2016

Specialty Overview by Prior Authorization Approval or Denial 2nd Quarter 2016 Specialty Overview by Prior Authorization Approval or 2nd Quarter 2016 3961 DERMATOLOGY Humira RHEUMATOID ARTHRITIS Approval Approved from 04/13/2016 thru 04/13/2018 3961 DERMATOLOGY Stelara PSORIASIS

More information

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy

More information

2018 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA

2018 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA 2018 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) These drugs require authorization before dispensing

More information

Specialty Drug List - Sorted by Therapeutic Class Developed for the Mississippi Division of Medicaid by Mercer

Specialty Drug List - Sorted by Therapeutic Class Developed for the Mississippi Division of Medicaid by Mercer ANTI-INFECTIVE ABELCET 100 MG/20 ML VIAL 4/1/2017 ANTI-INFECTIVE AMBISOME 50 MG VIAL 4/1/2017 ANTI-INFECTIVE ANCOBON 250 MG CAPSULE 4/1/2017 ANTI-INFECTIVE ANCOBON 500 MG CAPSULE 4/1/2017 ANTI-INFECTIVE

More information

ALPHA1-PROTEINASE INHIBITOR

ALPHA1-PROTEINASE INHIBITOR Ally Rx D-SNP Current as of Nov. 1, 2018 ALPHA1-PROTEINASE INHIBITOR ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG GLASSIA PROLASTIN-C INTRAVENOUS RECON SOLN ZEMAIRA PA Documentation of diagnosis, lab results,

More information

Essential Health Benefits Standard Specialty PA and QL List July 2016

Essential Health Benefits Standard Specialty PA and QL List July 2016 Anti-infectives Antiretrovirals, HIV SELZENTRY (maraviroc) Cardiology Antilipemic Pulmonary Arterial Hypertension Central Nervous System Anticonvulsants Depressant Neurotoxins Parkinson's Sleep Disorder

More information

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization 2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of March 31, 2018 207 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic

More information

May 2016 P & T Updates

May 2016 P & T Updates Commercial Triple Tier 4th Tier Applicabl e Traditional Detailed s 2 films - DESCOVY 2 2 1 tablet NARCAN 2 2 ODEFSEY 2 2 1 tablet REPATHA 2 2 HoFH: 3 ml per 28 ROSUVASTATIN 1 1 - UPTRAVI 3 2 - Alternatives

More information

Presbyterian Health Plan, Inc. Presbyterian Insurance Company, Inc. NOTIFICATION OF FORMULARY CHANGES

Presbyterian Health Plan, Inc. Presbyterian Insurance Company, Inc. NOTIFICATION OF FORMULARY CHANGES NOTIFICATION OF FORMULARY CHANGES The following summary describes changes to the 2017 Presbyterian Individual and Family Metal Plan/Employer Group Metal Plan Formularies effective 2018. For the most recent

More information

Injectable Drugs Requiring Pre-Service Approval

Injectable Drugs Requiring Pre-Service Approval Abatacept Orencia J0129, 10 mg 1500 FL LCD- L29051 1) For patients with rheumatoid arthritis with failure, intolerance or contraindications to methotrexate. Limit dosing to 40 mg Q 2 weeks. 2) For patients

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of November 30, 2017 188 joint negotiations have been completed** for the following drugs and indications: Drug Product Abilify Maintena

More information

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization 2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services

More information

Specialty Pipeline Update

Specialty Pipeline Update Specialty Pipeline Update D Drug Insights > December 2016 New drug information Rubraca (rucaparib): The U.S. Food and Drug Administration (FDA) granted accelerated approval to Clovis Oncology, Inc. s Rubraca

More information

Prior Authorization Program

Prior Authorization Program Prescription Drug List January 2011 Prior Authorization Program The prior authorization program helps us offer broad prescription drug coverage and promotes safe, clinically appropriate drug usage. Under

More information

Chemotherapy 101 for Radiation Oncology Workers

Chemotherapy 101 for Radiation Oncology Workers Chemotherapy 101 for Radiation Oncology Workers James Sinclair, M.D. CCARE/Medical Director Scripps Cancer Center March 9, 2013 Category 1) Alkylating agents Alkylating agents directly damage DNA to prevent

More information

Specialty Overview by Prior Authorization Approval or Denial 4th Quarter 2016

Specialty Overview by Prior Authorization Approval or Denial 4th Quarter 2016 Specialty Overview by Prior Authorization Approval or 4th Quarter 2016 Carrier Physician Specialty Drug Drug Class Decision Comments Reporting Year Reporting Month 3961 GASTROENTEROLOGY Humira RHEUMATOID

More information

2017 MDwise HIP Medical Services that Require Prior Authorization

2017 MDwise HIP Medical Services that Require Prior Authorization 2017 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of May 31, 2018 Pan-Canadian Pharmaceutical Alliance: Completed Negotiations 215 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic Name)

More information

MDwise Self-Administered Codes for Medical

MDwise Self-Administered Codes for Medical The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively

More information

NICE TA Adherence Check list April Drug Indication NICE Approval Release Date

NICE TA Adherence Check list April Drug Indication NICE Approval Release Date NICE TA Adherence Check list April 2014 Drug Indication NICE Approval Release Date Bortezomib Multiple myeloma (induction therapy) Afatinib Rituximab Pixantrone Aflibercept Teriflunomide Fluocinolone acetonide

More information

ADCIRCA. Products Affected Adcirca. Prior Authorization Criteria 2017 MMP Effective Date: 11/01/2017 Approval Date: 11/01/2017

ADCIRCA. Products Affected Adcirca. Prior Authorization Criteria 2017 MMP Effective Date: 11/01/2017 Approval Date: 11/01/2017 Prior Authorization 2017 MMP Effective Date: 11/01/2017 Approval Date: 11/01/2017 ADCIRCA Products Affected Adcirca PA Details All FDA-approved indications not otherwise Other Patients taking nitrates

More information

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior

More information

Presbyterian Health Plan, Inc. Presbyterian Insurance Company, Inc. NOTIFICATION OF FORMULARY CHANGES

Presbyterian Health Plan, Inc. Presbyterian Insurance Company, Inc. NOTIFICATION OF FORMULARY CHANGES NOTIFICATION OF FORMULARY CHANGES The following summary describes changes to the Presbyterian Commercial Large Group Plans (Non-Metal Plans) Formularies effective 2018. For the most recent list of drugs,

More information

NICE TA Adherence Check List

NICE TA Adherence Check List NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of August 31, 2018 235 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic

More information

Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee Implementation

Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee Implementation NICE Technology Appraisals - Time to Implementation Report - 3 rd August 2015 Produced by Tracy Steadman, Croydon Public Health Intelligence Team, Croydon Council Date of Guidance Title of Guidance Summary

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of September 30, 2018 241 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of December 31, 2018 262 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic

More information

Drug Name Description of Change Formulary Coverage Formulary Alternative(s)

Drug Name Description of Change Formulary Coverage Formulary Alternative(s) NOTIFICATION OF FORMULARY CHANGES The following summary describes changes to the Presbyterian Centennial Care Formulary effective 2018. For the most recent list of drugs, information on asking for a prior

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review

More information

PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017

PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017 PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017 A meeting of the Health Partners Pharmacy and Therapeutics (P&T) Committee was held on September and December 2017. The following are the recommendations

More information

Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class

Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Cancer LAST REVIEW 9/11/18 THERAPEUTIC CLASS Oncology REVIEW HISTORY 5/17, 5/16 LOB AFFECTED Medi-Cal (MONTH/YEAR) This policy

More information

2019 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA

2019 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA 2019 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) These drugs require authorization before dispensing

More information

BCN Advantage SM requirements for drugs covered under the medical benefit

BCN Advantage SM requirements for drugs covered under the medical benefit J0586 ABOBOTULINUMTOXINA Dysport X X X the medication is being used to treat J0178 AFLIBERCEPT Eylea X X X X X of Neovascular (Wet) -Related Macular Degeneration of Macular Edema following either central

More information

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal

More information

INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]

INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY] Commercial Medical Oncology Program Review Code List 3rd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of

More information

Ally Rx D-SNP Current as of r 1, 2017

Ally Rx D-SNP Current as of r 1, 2017 Ally Rx D-SNP Current as of r 1, 2017 AMPYRA AMPYRA PA Moderate to severe renal impairment (CrCL less than or equal to 50ml/min), patient not able to walk 25 feet in 8-45 seconds. Documentation of diagnosis,

More information

Prior Authorization Program Information (Effective April 1st, 2018)

Prior Authorization Program Information (Effective April 1st, 2018) Prior Authorization Program Information (Effective April 1st, 2018) Prior Authorization Certain drugs require prior authorization to help promote safe, quality and affordable pharmacy care. Your doctor

More information

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Table S1 Therapeutic biologic product approvals, classes and innovation categories: 16 24 Approval year Trade name Active Ingredient(s) Drug class Innovation category Approval date 16 Intron-A Interferon

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

Cosentyx. Cosentyx (secukinumab) Description

Cosentyx. Cosentyx (secukinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx

More information